Search alternatives:
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
data decrease » rate decreased (Expand Search), deaths decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ patient » _ patients (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
data decrease » rate decreased (Expand Search), deaths decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ patient » _ patients (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
-
1
-
2
-
3
HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters
Published 2025“…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Structure model predictions of wildtype and A398E/V and M1425V/I Ca<sub>V</sub>3.3 channels.
Published 2025Subjects: -
12
-
13
-
14
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
18
-
19
-
20
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: